An NR2B-Dependent Decrease in the Expression of trkB Receptors Precedes the Disappearance of Dopaminergic Cells in Substantia Nigra in a Rat Model of Presymptomatic Parkinson's Disease by Riquelme, Eduardo et al.
Hindawi Publishing Corporation
Parkinson’s Disease
Volume 2012, Article ID 129605, 14 pages
doi:10.1155/2012/129605
Research Article
An NR2B-DependentDecrease in the Expression of
trkB ReceptorsPrecedestheDisappearanceofDopaminergic
C ellsinS ub s t a ntiaN igrainaR a tM od elo fP r es ympt o ma tic
Parkinson’s Disease
EduardoRiquelme,1 Jorge Abarca,1 Jorge M.Campusano,1 andGonzalo Bustos1,2
1Departamento de Biolog´ ıa Celular y Molecular, Facultad de Ciencias Biol´ ogicas, Pontiﬁcia Universidad Cat´ olica de Chile,
Alameda 340, 8331150 Santiago, Chile
2Programa de Biomedicina, Universidad San Sebasti´ an, Za˜ nartu 1482, ˜ Nu˜ noa, 7780272 Santiago, Chile
Correspondence should be addressed to Jorge M. Campusano, jcampusano@bio.puc.cl and Gonzalo Bustos, gbustos@bio.puc.cl
Received 10 January 2012; Revised 19 March 2012; Accepted 2 April 2012
Academic Editor: Kah-Leong Lim
Copyright © 2012 Eduardo Riquelme et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Compensatory changes occurring during presymptomatic stages of Parkinson’s disease (PD) would explain that the clinical symp-
toms of the disease appear late, when the degenerative process is quite advanced. Several data support the proposition that brain-
derived neurotrophic factor (BDNF) could play a role in these plastic changes. In the present study, we evaluated the expression of
the speciﬁc BDNF receptor, trkB, in a rat model of presymptomatic PD generated by intrastriatal injection of the neurotoxin
6-OHDA. Immunohistochemical studies revealed a decrease in trkB expression in SN pars compacta (SNc) seven days after
6-OHDA injection. At this time point, no change in the number of tyrosine hydroxylase (TH) immunoreactive (TH-IR) cells
is detected, although a decrease is evident 14 days after neurotoxin injection. The decrease in TH-positive cells and trkB expression
in SNc was signiﬁcantly prevented by systemic administration of Ifenprodil, a speciﬁc antagonist of NR2B-containing NMDA
receptors. Therefore, an NR2B-NMDA receptor-dependent decrease in trkB expression precedes the disappearance of TH-IR cells
in SNc in response to 6-OHDA injection. These results support the idea that a functional coupling between NMDA receptors
and BDNF/trkB signalling may be important for the maintenance of the dopaminergic phenotype in SNc during presymptomatic
stages of PD.
1.Introduction
Parkinson’s disease (PD) a progressive degenerative disorder
that is characterized by the disappearance of dopaminergic
neurons of the nigrostriatal pathway. The clinical symptoms
ofPDdevelopslowlyandgraduallyandareonlyevidentafter
50–60% of dopamine (DA) cells loss in substantia nigra (SN)
and 70–80% decrease of striatal DA content has occurred
[1–4]. Compensating responses and plastic changes in the
dopaminergic nigrostriatalsystem during presymptomatic
PD would be responsible for the delay in the appearance
of the clinical symptoms of the disease [5–10]. Emerging
evidence suggests that changes in the expression of brain-
derived neurotrophic factor (BDNF) in SN may be one of
the molecular signals associated with responses occurring in
basal ganglia during presymptomatic PD [11]. In agreement
with this, a number of studies have demonstrated transient
increases of BDNF mRNA and protein in SN, early after
partial lesions of the nigrostriatalDA pathway in a rat pres-
ymptomatic model of PD [11–13]. These changes in the
expression of BDNF could play an important role during the
compensatorychangesatearlystagesofPD.Thisisconsistent
with reports indicating that BDNF increases the survival of
DA neurons [14–17] and that an augmentation of BDNF
levelsinbasalgangliamaypreventdegenerationoftheseneu-
rons in a rat model of PD [18]. Conversely, inhibiting endo-
genous BDNF expression by antisense oligonucleotide infu-
sion causes loss of nigral dopaminergic neurons in SN [19].2 Parkinson’s Disease
Interestingly, the disappearance of dopaminergic neurons in
SN has been also observed when BDNF levels are normal,
but its ability to bind or activate its speciﬁc receptor, tropo-
myosin-related kinase B (trkB), has been impaired [20, 21].
These ﬁndings indicate the importance of trkB receptor acti-
vation in order to generate a full BDNF-induced response in
SN. Along this idea, old mutant mice showing haploinsuﬃ-
ciency for trkB exhibit a greater loss of DA neurons in the SN
when compared to old wild-type animals [17], which further
suggests a possible participation of this receptor in the devel-
opment of PD.
TrkB is a tyrosine kinase-type receptor, which belongs to
the family of trk receptors that binds neurotrophins, event
linked to cell survival and synaptic plasticity [22–24]. TrkB
and BDNF are both expressed in dopaminergic neurons
located in SN [25–28], which suggests that BDNF exerts
autocrine/paracrine functions in this nucleus.
We have recently reported a coupling between increased
glutamate release, NMDA receptor activation, and BDNF
expression in the adult SN, which represents an important
molecularsignaltriggeredinthisbrainnucleusinresponseto
theearlyandpartialDAlossthatoccursinstriatalnerveend-
ingsduringpresymptomaticPD[13].Thesefunctionalinter-
actions occurring in SN could account in part for adaptive
and plastic responses associated with early PD. Conversely,
no data are available on the expression of trkB receptors in
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possibility that glutamate receptors could modulate trkB
expression over the progression of the disease. In the present
study,byusingimmunohistochemistryandinsituhybridiza-
tion, we evaluated the expression of trkB in SN at diﬀerent
time points in a rat model of presymptomatic PD and com-
pare it to the expression of the DA cell marker, Tyrosine
hydroxylase (TH). In addition to this, we also assessed the
possibility that glutamate receptors might modulate the
expression of trkB receptors in SN. Preliminary version of
this data has been previously reported in poster format [29].
2.MaterialsandMethods
2.1. Animals. Rats weighing 260–300g were obtained from
the Animal Service Unit at the Pontiﬁcia Universidad
Catolica de Chile and were handled according to the regu-
lations stipulated by the Bioethics and Biosafety Committee
of the Faculty of Biological Sciences, Pontiﬁcia Universidad
Cat´ olica de Chile, and by The Animal Care and Use
Committee of FONDECYT, Chile.
2.2. 6-Hydroxydopamine (6-OHDA) Lesions. Lesions were
carried out as reported [13]. Brieﬂy, adult male Sprague-
Dawley rats were anesthetized with chloral hydrate (400mg/
kg, i.p.) and mounted in a stereotaxic apparatus (Stoelting).
Twenty micrograms of 6-OHDA in 4μL of 0.02% ascorbic
acid was injected in the right striatum at a rate of 0.5μL/min.
Coordinates for the injection of the neurotoxin were A:
1.2mm, L: 2.8mm, and V: 4.5mm, with respect to Bregma,
according to the atlas of Paxinos and Watson [30]. Sham-
operated rats were stereotaxicallyinjected with 4μL of 0.02%
ascorbic acid using the same coordinates. The rats were
allowed to recover for four, seven, and fourteen days, prior
to conducting the experiments described hereinafter.
2.3. Preparation of Brain Tissue for Staining. Procedure has
been previously reported [13]. Rats were anesthetized with
chloral hydrate (400mg/kg; i.p.) and transcardially perfused
with saline (0.9% NaCl), followed by ice-cold ﬁxative solu-
tion (3% paraformaldehyde, 15% picric acid, 0.1% glutaral-
dehyde,inphosphatebuﬀeredsalinesolution(PBS)(pH7.4).
Brainswereremovedfromtheskullandpostﬁxedfor30min.
Brains were then dehydrated in 25% sucrose solution for
48hr at 4◦C. Afterwards, 20–30μm thick coronal slices were
prepared on a cryostat (CM 1510; Leica, Heidelberg, Ger-
many) at 5.2 to 5.6mm posterior to Bregma, the brain
region where SN is located according to the atlas of Paxinos
andWatson[30].Whenﬂuorescence-baseddoubleimmuno-
histochemistry and nonisotopic in situ hybridization (ISH)
studieswerecarriedout,theprocedureusedwasasdescribed
here, except that the ﬁxative solution was ice-cold 4% para-
formaldehyde in PBS.
2.4. Immunohistochemical (IHC) Studies. Free-ﬂoating coro-
nal midbrain slices were treated with 0.5% H2O2, rinsed
several times in 0.1M PBS, and then incubated in blocking
solution (3% normal goat serum, 0.02% sodium azide, 0.2%
Triton X-100 in PBS) for 60min. Then, slices were incubated
for 72 hours at 4◦C with the primary antibodies of interest
in blocking solution. The slices were then washed in PBS
and reacted with a biotinylated goat anti-rabbit IgG (Vector
Laboratories) in PBS containing 0.4% BSA and 0.1% Triton
X-100,twohoursatroomtemperature.Afterwards,theslices
were rinsed in 0.1M PBS and the immunoreactivity (IR) was
visualized with a standard avidin-biotin-peroxidase reagent
(1:250 dilution, ABC Elite Kit; Vector Laboratories) for
90minatroomtemperature.IHClabellingwasrevealedwith
0.05% diaminobenzidine (in 0.05% NiCl and 0.01% H2O2-
Tris saline buﬀer, pH 7.6) and then observed under light
microscopy and the number of trkB-immunoreactive (trkB-
IR) cells in SN determined by image analysis as described
hereinafter. For TrkB staining, slices were incubated with a
1:1000dilutionofapolyclonalrabbitanti-trkB(sc-12,Santa
Cruz Biotechnology). TrkB-like IR signals were totally
blocked when brain tissue coronal slices were incubated with
anti-trkBantibodytogetherwithanexcessamount(100X)of
theimmunizing peptide (sc-12P,SantaCruzBiotechnology).
In addition, negative controls made by omission of the ﬁrst
antibody did not reveal IR signals. A 1:5000 dilution of a
polyclonal rabbit anti-TH antibody (Calbiochem) was used
for IHC labelling of TH-containing neurons, as reported
previously by us [12].
For double immnunoﬂuorescent experiments, free-
ﬂoating coronal brain slices were rinsed in 0.1M PBS buﬀer
containing 3% normal goat serum, 0.02% sodium azide, and
0.2% Triton X-100, for 1hr at room temperature. Then, the
slices were incubated for 72 hours at 4◦C in presence of
a 1:1000 dilution of the anti-trkB antibody (Santa Cruz
Biotechnology) and a 1:2000 dilution of a polyclonal mouseParkinson’s Disease 3
anti-TH antibody (Calbiochem). Thereafter, the slices were
incubated for 1 hour at room temperature with a 1:200
dilution of secondary CY3-conjugated anti-rabbit antibody
(Jackson ImmunoResearch) and a 1:50 dilution of Fluo-
rescein- (FITC-) conjugated anti-mouse antibody (Jackson
ImmunoResearch). Finally, the slices were mounted and
coverslipped for ﬂuorescence microscopic analysis.
2.5.NisslStaining. ToperformaNisslstaining,coronalbrain
slices were sequentially immersed in the following solutions:
xylene, ethanol (at 100%, 95%, and 70%), water, 0.5% cresyl
violet(30min),water,andethanol(at70%,90%,and100%).
Finally, the tissue slices were mounted on gelatinized glass
slides,driedovernight,andobservedunderlightmicroscopy.
2.6. Nonisotopic In Situ Hybridization (ISH) of TrkB. The
procedure used was essentially as reported previously by us,
with slight modiﬁcations [31].
2.6.1. Labelling of Oligonucleotide Probe. Deoxynucleotide
probes(41-mer)synthesizedbyBIOS-Chile(Santiago,Chile)
were used for ISH experiments. TrkB antisense probe 5 -
GTG GAG GGG ATC TCA TTA CTT TTG TTT GTA GTA
TCC CCG AT-3  was complementary to nucleotides 1880–
1920ofthereportedtrkBsequence(M-55291).Onehundred
picomoles of trkB probe were 3  endlabeled by incubation
with55unitsofterminaltransferasein20μLoftailingbuﬀer,
in presence of 9nmol of dATP and 1nmol of digoxigenin-
labeleled deoxyuridine-triphosphate (DIG-dUTP).
2.6.2. Hybridization Reaction and Immunological Detection.
BraincoronalsectionswererinsedinPBSandthenincubated
at 62◦C for 30min in a prehybridization solution containing
Denhardt’s 1X (Denhardt’s 100X composition: 2% Ficoll,
2% polyvinil pyrrolidone, 2% BSA) and SSC 4X (SSC 20x
composition: 3M NaCl, 0.3M sodium citrate). Thereafter,
the tissue slices were incubated in presence of 10pmol/mL
trkB DIG-labeled antisense probes, in a buﬀer containing
50% formamide, 0.6M NaCl, 20mM EDTA, and 0.2% lauryl
sarcosine, in Tris-HCl, pH 7.5, for 20hr at 35◦C. After hybri-
dization, the slices were rinsed in SSC and then reacted with
an anti-DIG antibody conjugated to alkaline phosphatase
(Boehringer-Mannheim Gmbh Biochemica, Germany).
Reaction was developed using NBT and BCIP (Gibco, MD)
as enzyme substrates. Finally, the slices were mounted on
gelatinized glass slides, dried overnight, and coverslipped
for light microscopy. As a control, the tissue slices were
hybridized as explained previously, in presence of an excess
(100X) of unlabeled trkB probe. As a diﬀerent experimental
control, the slices were incubated with a sense oligonucleo-
tide probe labeled with DIG-UTP. These controls generated
no positive signals (data not shown).
2.7. Analysis of TrkB and TH Expression in SN. After IHC
or ISH procedures, brain sections were examined under a
light microscope (Nikon Labophot-2) equipped with a video
camera (Sony CCD-Iris) connected to a Macintosh com-
puter. Positive cells for trkB or TH immunostaining and
trkB-DIG labelled cells in SN were counted using the NIH
image//ppc 1.61 program. For each experimental paradigm,
the number of positive cells was evaluated in three diﬀerent
areas per slice, and results shown hereinafter correspond to
data obtained from at least four diﬀerent rats, in which at
least three diﬀerent slices per rat were studied. Only coronal
slices corresponding to 5.2 to 5.6mm posterior to Bregma
were used [30].
The number of cells with positive labelling was counted
in photomicrographs (20x magniﬁcation), with sample areas
of 0.042mm2 for SNc and 0.065mm2 f o rS Np a r sr e t i c u l a t a
(SNr).Thus,rawresultsobtainedareestimatesofcelldensity
in each condition. Results are reported as percentage of
cells in the ipsilateral SN compared to the contralateral side
(100%) in each experimental condition.
Immunoﬂuorescence results were examined under a Flu-
oview 100 confocal microscope and an Olympus microscope
(Olympus BX51, USA) equipped with a ﬂuorescent system.
Positive cells were counted using the Q-Capture Pro software
(Q-Imaging, Canada). The number of positive cells for each
of the IF was evaluated in each slice as indicated previously,
under a 40x magniﬁcations, with sample areas of 0.020mm2
for each SNc. Results represent the percentage of cells in SN
compacta that exhibit colabelling of TH and trkB over the
total number of TH IF-positive cells present in this midbrain
subregion.
2.8. Statistical Analysis. All statistical analysis were per-
formed using Prism 4.01 GraphPad software. Data were ana-
lyzed by Kruskal-Wallis nonparametric ANOVA, followed by
a U-test. Values of P<0.05 were considered statistically sig-
niﬁcant. All data are reported as means ± S.E.M.
3. Results
3.1. A Decrease in the Expression of TrkB-IR Cells and TrkB
mRNA Precedes the Disappearance of TH-IR Cells in SNc of
Rats after Unilateral 6-OHDA Intrastriatal Injections. In our
laboratory, we have recently used an animal model proposed
to imitate the presymptomatic stages of PD [3, 32]. By using
this model, which consists of a unilateral intrastriatal injec-
tionoftheneurotoxin6-OHDA,wehaveshownaprogressive
reduction in rat striatal DA levels 1 to 7 days after neurotoxin
injection[13].WealsoshowedthatinSNc,theIRforTH,the
key enzyme in the synthesis of DA and a common marker
for dopaminergic neurons, is decreased by 14 days after
neurotoxin injection [13].
Expandingthosestudies,weanalyzedthenumberofTH-
IR cells in SNc of rats 4, 7, and 14 days after unilateral 6-
OHDA intrastriatal injection (Figure 1). We did not visualize
changes in the number of TH-IR cells in ipsilateral SNc 4 or
7 days after unilateral 6-OHDA intrastriatal injections, when
compared to the contralateral SNc of the respective animal
(Figures 1(a) and 1(b) and Figures 1(c) and 1(d),a t4a n d7
days, resp.). However, as shown previously [13], we detected
a decrease in the number of TH-IR cells in the ipsilateral SNc
14 days after neurotoxin injection compared to its con-
tralateral side (Figures 1(e) and 1(f)). Quantiﬁcation of data4 Parkinson’s Disease
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Figure 1: The unilateral intrastriatal injection of 6-OHDA induces a decrease in the number of TH immunoreactive cells in SNc that is
only evident 14 days after the neurotoxin injection. Photomicrographs show TH-immunoreactive (IR) cells in the contralateral (a), (c), and
(e) and ipsilateral (b), (d), and (f) side of rat SN 4, 7, and 14 days after unilateral 6-OHDA intrastriatal injection, respectively. (a)–(f) scale
bar = 100μm. SNc: substantia nigra pars compacta; SNR: substantia nigra pars reticulata. (g) Percentage of TH-IR cells in the ipsilateral SNc
compared to the contralateral side, at 4, 7, and 14 days after unilateral intrastriatal 6-OHDA (black columns) or ascorbic acid (sham, white
columns) injections to rats. The number of cells with TH-IR signals per unit area per slice was 507.9 ± 7.8, 484.1 ± 71.4, and 531.7 ± 103.2
cells/mm2 incontralateralSNcofascorbateinjectedrats,at4,7,and14daysaftertreatment,respectively.Inthecaseof6-OHDA-treatedrats,
the number of cells with TH-IR signals in contralateral SNc was 500.0±23.8, 452.4±87.3, and 507.9±111.1c e l l s / m m 2,a t4 ,7 ,a n d1 4d a y s
after neurotoxin injection, respectively. n = 6 rats under each experimental condition. The diﬀerent experimental groups were compared by
a Kruskal-Wallis nonparametric ANOVA, followed by a U-test. ∗P<0.05 compared with sham-treated rats.
obtained in several animals after 6-OHDA and sham treat-
ment is shown in Figure 1(g). We only detected a statistically
signiﬁcant reduction in the relative number of TH-IR cells
in SNc two weeks after striatal neurotoxin administration
(48.6% ± 3.4, P<0.01, 6-OHDA versus sham treatment)
and no diﬀerences were observed at earlier time points
(Figure 1(g)). Interestingly, the number of Nissl-stained cells
in ipsilateral SNc remained unaﬀe c t e d4t o7d a y sa f t e rParkinson’s Disease 5
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Figure 2: Photomicrographs showing a decrease in the number of trkB-IR cells in ipsilateral SNc at 7 and 14 days, but not at 4 days, after
unilateral 6-OHDA intrastriatal injections. Photomicrographs show trkB-immunoreactive (IR) cells in the contralateral (a), (c), and (e) and
ipsilateral (b), (d), and (f) sides of rat SN at 4, 7, and 14 days after unilateral intrastriatal injection of 6-OHDA. (a)–(f) scale bar = 100mm.
SNc: substantia nigra pars compacta; SNR: substantia nigra pars reticulata.
unilateral 6-OHDA intrastriatal injection (102 ± 4a n d9 3±
5% of cells in ipsilateral SNc compared to contralateral side
at 4 and 7 days after neurotoxin injection, resp.; P>0.05).
It was only possible to detect a reduction in the number of
Nissl-positive cells 14 days after neurotoxin injection (47 ±
7% of cells in ipsilateral SNc compared to the contralateral
side; P<0.05). Altogether, these results demonstrate that the
number of TH-IR cells and Nissl-stained cells in SNc is only
modiﬁed 2 weeks after an intrastriatal injection of 6-OHDA,
consistent with a progressive model of PD and with previous
results from us and others [12, 33–35].
We have previously shown a transient increase in the
genic expression of BDNF in the ipsilateral SN as early as
1 day after a unilateral intrastriatal injection of 6-OHDA and
prior to the disappearance of TH-IR cells in SNc [13]. In this
work, we decided to evaluate the expression of trkB, the
speciﬁc BDNF receptor, in SN, using the same experimental
paradigm.
Photomicrographs shown in Figures 2(a), 2(c),a n d2(e),
are representative of the distribution of trkB-IR cells in
control SN and are consistent with data in the literature [36,
37].ImmunoreactivecellsconcentratedenselyinSNcwhileit
is also possible to detect a small number of labeled cells
scattered over the Substantia Nigra pars reticulata (SNR).
This pattern of trkB-IR is dramatically aﬀected in the ipsi-
lateral side of SN at 7 and 14 days after unilateral intras-
triatal 6-OHDA injection. The disappearance of the dense
immunoreactivity for trkB in SNc (Figures 2(d) and 2(f))i s
especially remarkable. In contrast, these studies exhibited no
change in the distribution of trkB-IR cells in ipsilateral SNc6 Parkinson’s Disease
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Figure 3: Unilateral 6-OHDA intrastriatal injection results in a signiﬁcant decrease in the number of trkB-IR cells in ipsilateral SNc at 7 and
14 days after the injection. (a) Percentage of trkB-IR cells in rat ipsilateral SNc compared to the contralateral side after unilateral 6-OHDA
(black columns) or ascorbic acid (sham, white columns) intrastriatal injections. Number of cells with trkB-IR signals in contralateral SNc of
ascorbate-injected rats per area unit per slice was 507.9 ± 7.9, 365.1 ± 15.9, and 412.7 ± 10.6c e l l s / m m 2, at 4, 7, and 14 days after injections,
respectively. In the case of 6-OHDA-treated rats, number of cells with trkB-IR signals in contralateral SNc was 484.1 ± 15.9, 381.0 ± 31.7
and 404.7 ± 15.9c e l l s / m m 2, at 4, 7, and 14 days after 6-OHDA injections, respectively. (b) Percentage of trkB-IR cells in the ipsilateral SNR
compared to the contralateral side, at 7 and 14 days after unilateral intrastriatal injections of 6-OHDA (black columns) or ascorbic acid
(sham, white columns). Number of cells with trkB-IR signals in contralateral SNR of ascorbate-treated rats was 117.9 ± 5.1 and 143.6 ± 5.1
cells/mm2, at 7 and 14 days after injections, respectively. In the case of 6-OHDA-treated rats, the number of cells with trkB-IR signals in
contralateral SNR amounted to 117.9±5.1 and 148.7±10.3c e l l s / m m 2, at 7 and 14 days after toxin injections, respectively. n = 6 rats under
each experimental condition. The diﬀerent experimental groups were compared by a Kruskal-Wallis nonparametric ANOVA, followed by a
U-test. ∗P<0.05 compared with sham-treated rats.
as compared to contralateral SNc 4 days after unilateral
6-OHDA injections (Figures 2(a) and 2(b)). Quantiﬁcation
of the number of trkB-IR cells in ipsilateral SN was per-
formed at 4, 7, and 14 days after 6-OHDA or ascorbic acid
(sham-treated) unilateral intrastriatal injections (Figure 3).
Data are presented as percent change in the number of trkB-
IR cells in ipsilateral SNc (Figure 3(a))o rS N R( Figure 3(b))
compared to the respective contralateral side, in both sham-
and 6-OHDA-treated animals. A signiﬁcant 40 ± 3% and
40 ± 1.5% reduction in the relative number of trkB-IR cells
in ipsilateral SNc was detected in 6-OHDA-treated rats 7 and
14 days after intrastriatal injection of the neurotoxin when
compared to sham animals, respectively (P<0.05 in each
case) (Figure 3(a)). No diﬀerences were observed when com-
paring the relative number of trkB-IR cells in ipsilateral SNc
4 days after unilateral 6-OHDA or ascorbic acid injections
(Figure 3(a)). Interestingly, the reduction in trkB-IR cells
observed at 7 and 14 days after 6-OHDA seems to be a sub-
regionspeciﬁcphenomenoninSNsincenochangeintherel-
ative number of trkB-IR cells was detected in ipsilateral SNR
at any time point after neurotoxin injection (Figure 3(b)).
The aforementioned changes in the number of trkB
immunoreactive cells in ipsilateral SNc after 6-OHDA injec-
tion could be explained by a transcriptional mechanism; that
is, the genic expression of trkB could be reduced in this
midbrain nucleus after the neurotoxin striatal injection. To
provide evidence regarding this proposition, the distribution
and number of cells expressing trkB mRNA in SN were
evaluated by nonisotopic ISH seven days after the unilateral
6-OHDA intrastriatal injection. Seven days of 6-OHDA
treatment was chosen for these ISH studies as no changes in
Nissl-stained cells or in TH-IR cells were detected in ipsilat-
eral SNc at this time point after neurotoxin injection com-
pared to sham rats, as indicated previously. The ISH studies
revealed a high concentration of cells expressing trkB mRNA
in SNc and a more disperse localization of trkB mRNA-
expressing cells in SNR, as it is shown in contralateral SN in
Figure 4(a). However, this pattern of trkB mRNA expression
is quite diﬀerent in ipsilateral SN at 7 days after unilateral
intrastriatal injection of the neurotoxin (Figure 4(b)), since
it is possible to observe a diﬀuse distribution of DIG-labeled
cells throughout the SN in conjunction with a relative
decrease in the number of these cells in SNc. The evaluation
ofthenumberoftrkB-DIGlabeledcellsinipsilateralSNcat7
days after unilateral striatal 6-OHDA injection, expressed as
percentof change over the contralateralSNc, revealed a 38 ±
4% decrease compared to sham-treated rats (Figure 4(c),
P<0.05). Conversely, no statistical diﬀerences were detected
when comparing the number of cells expressing the mRNA
for trkB in ipsilateral SNR after 6-OHDA or ascorbic acid
striatal injections (Figure 4(d)). These results are consistent
with those obtained before by IHC and raise the possibility
that the speciﬁc decrease in the expression of trkB observed
in ipsilateral SNc, in response to 6-OHDA injection in the
striatum, might be mediated at least in part by a transcrip-
tional mechanism.
3.2.DopaminergicNeuronsofSNcFailtoExpressTrkBatEarly
Stages after 6-OHDA Striatal Administration. The aforemen-
tioned results demonstrate that as early as seven days after
the unilateral intrastriatal injection of 6-OHDA, it is possibleParkinson’s Disease 7
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(c) Quantiﬁcation of trkB-DIG labeled cells in SNc.
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Figure 4: A speciﬁc decrease in the number of positive trkB-mRNA cells is observed in ipsilateral SNc 7 days after unilateral 6-OHDA
intrastriatal injections. Photomicrographs from ISH experiments show trkB-DIG positive cells in the contralateral side (a) and ipsilateral
side (b) of rat SN 7 days after unilateral 6-OHDA intrastriatal injection, respectively. (a), (b) scale bar = 100μm. SNc: substantia nigra pars
compacta; SNR: substantia nigra pars reticulata. (c) Percentage of trkB-DIG positive cells in the ipsilateral SNc compared with the
contralateral side, 7 days after unilateral intrastriatal 6-OHDA (black columns) or ascorbic acid (sham, white columns) injections to rats.
Number of cells with trkB-DIG-positive signals in contralateral SNc was 285.7±15.9 and 317.5±31.7c e l l s / m m 2 in ascorbate and 6-OHDA
injected rats, respectively. (d) Percentage of trkB-DIG positive cells in the ipsilateral SNR compared to the contralateral side, 7 days after
unilateral intrastriatal 6-OHDA (black columns) or ascorbic acid (sham, white columns) injections to rats. Number of cells with trkB-DIG
positive signals in contralateral SNR was 107.7 ± 5.1 and 117.9 ± 5.1c e l l s / m m 2 in ascorbate and 6-OHDA injected rats, respectively. n = 4
rats under each experimental condition. The diﬀerent experimental groups were compared with a Kruskal-Wallis nonparametric ANOVA,
followed by a U-test. ∗P<0.05 compared with sham-treated rats.
to detect a decrease in the number of trkB-IR cells in SNc
(Figures 2 and 3) without a change in the number of TH-
positive cells in this midbrain subarea (Figure 1). On the
other hand, the total number of cells detected by Nissl
staining remained unchanged in SNc at this time point after
6-OHDA treatment. Therefore the early decrease in trkB-IR
cells might be the consequence of a reduced expression of
trkB in the population of dopaminergic neurons and not due
to the disappearance of these neurons in SNc. We decided to
evaluate this proposition.
We ﬁrst studied the expression of trkB in TH-positive
cells by double immunoﬂuorescence (IF), in na¨ ıve control
animals. As expected, TH-IF positive cell bodies are only
observed in SNc (Figure 5(a)). Even though there are no
TH-positive cell bodies in SNR, it is possible to observe a
signiﬁcantnumberofTH-IFlabeledneuritesprojectingfrom
the SNc to the SNR (Figure 5(a)). On the other hand, IF
studies exhibited trkB-positive cells in both SNc and SNR
(Figure 5(b)), in agreement with the IHC results shown
before. When both images are merged, it is possible to
observe colocalization of TH-IF and trkB-IF in SNc, while
this colocalization does not occur in SNR (Figure 5(c)).
Indeed, approximately 80% of the total TH-IF cells in SNc
were found to coexpress trkB (see the following).
Immunoﬂuorescence studies conducted 7 days after
unilateral intrastriatal injection of 6-OHDA showed results
compatible with a reduction in the number of trkB-IF cells
inipsilateralcomparedtocontralateralSNc(Figures6(c)and
6(d)), while the number of TH-IF cells remained unchanged
(Figures 6(a) and 6(b)). In addition, the merge of these pic-
tures indicates a decrease in the number of cells coexpressing
TH and trkB in SNc ipsilateral to the striatal injection of
6-OHDA (Figures 6(e) and 6(f)). Indeed, quantiﬁcation of
the results obtained in several animals revealed a statistically
signiﬁcant reduction in the colocalization of TH-IF and
trkB-IF cells in ipsilateral SNc compared to its contralateral
side after neurotoxin treatment (39 ± 8% reduction, P<
0.05) (Figure 6(g)). No such change was observed in sham-
treated rats (Figure 6(g)). These results indicate that the
early decrease in trkB expression observed in ipsilateral
SNc after intrastriatal 6-OHDA injection is most likely due
to a reduced expression of the neurotrophin receptor in8 Parkinson’s Disease
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(b)
Colocalization
(c)
Figure 5: TH and trkB immunoreactivities are highly colocalized in rat SNc. Immunoﬂuorescent detection of TH (a) and trkB (b) in SN in
untreated na¨ ıve rats. (c) Merge of (a) and (b). (a)–(c) scale bar = 150μm. SNc: substantia nigra pars compacta; SNR: substantia nigra pars
reticulata.
TH-positive cells occurring in SNc and not to the disappear-
ance of these cells in this midbrain subregion.
3.3. Ifenprodil Inhibits Both TrkB Downregulation and TH
Decreased Expression in SNc Induced by a Unilateral 6-OHDA
Intrastriatal Microinjection. Recent results from us suggest
the induction of a coupling between Glutamatergic drive,
NMDA receptor activation, and increased BDNF expression
in SN at the very early stages of the present rodent model of
presymptomatic PD [11, 13]. Therefore, we sought to deter-
mine, by means of a Glutamate receptor antagonist, whether
NMDA receptors might be involved in the early decrease in
trkB expression as well as in the TH-IR cell disappearance
that is observed in SNc in response to 6-OHDA intrastriatal
injection. The selective NR2B-NMDA receptor antagonist,
ifenprodil, was chosen for these studies because of reports
indicating that activation of these receptor subtypes might
suppress BDNF/trkB receptor complex expression and initi-
ate or facilitate signaling cascades involved in neuronal cell
death [38].
In the following experiments, four groups of rats were
treated with consecutive i.p. injections of Ifenprodil (5mg/
kg)orsalinesolution,administered1daybeforeand3,5,and
7 days after 6-OHDA or ascorbic acid (sham rats) intrastri-
atal injection. A marked decrease in the relative expression
of trkB-IR cells occurs in the ipsilateral SNc of saline pre-
treated rats after 14 days of 6-OHDA intrastriatal injection
compared with the ipsilateral SNc of sham rats (Figure 7(a),
ﬁrst versus second column, P<0.05). Such 6-OHDA-
induced decrease of trkB-IR cells in the ipsilateral SNc was
signiﬁcantly prevented in rats pretreated with Ifenprodil
(Figure 7(a), second versus fourth column). Ifenprodil pre-
treatment also totally prevented the decrease of trkB expres-
sion observed in the ipsilateral SNc 7 days after neurotoxin
intrastriatal injection (41.4 ± 4% reduction versus 3.5 ±
0.4% reduction in the number of trkB-IR cells in the SNc
when comparing 6-OHDA injected rats versus 6-OHDA plus
Ifenprodil injected rats, P<0.01). On the other hand, saline
and Ifenprodil pretreatment produced no eﬀect on trkB-IR
cell numbers, as evidenced in the ipsilateral SNc of sham rats
(Figure 7(a), ﬁrst versus third column).
IHC studies with antibodies against TH were also con-
ducted in Ifenprodil- and saline-treated rats after unilateral
6-OHDA or ascorbic acid (sham) intrastriatal administra-
tion. The IHC studies illustrated in Figure 7(b) were per-
formed 14 days after neurotoxin or ascorbate injections. As
showninFigure 7(b),decreasesinthenumberofTH-IRcells
in the ipsilateral SNc are readily observed after 6-OHDA
striatal injections to saline pretreated rats (columns under
saline pretreatment, P<0.05). In contrast, Ifenprodil pre-
treatment blocked the appearance of such 6-OHDA-induced
decrease of TH-IR cells observed in SNc (Figure 7(b)).
On the other hand, decreases in the number of TH-IR cells
in SNc were not detected 7 days after 6-OHDA injection
(Figure 1) and the expression of TH observed at this time
point was not statistically modiﬁed by ifenprodil pretreat-
ment (P>0.05).
Therefore, these studies show that trkB expression in
SNc of rats may be decreased after a partial lesion of the
nigrostriatalDAergicneuronalpathwayinducedby6-OHDA
and that this decrease along with that of TH-IR occurring in
SNc may be prevented by NR2B-containing NMDA recep-
tors antagonists such as Ifenprodil.
4. Discussion
4.1. The 6-OHDA Presymptomatic Rat Model of Parkinson
Disease. OneofthemainpathologicalhallmarksofPDisthe
progressive and selective loss of dopaminergic neurons in
SN. The clinical symptoms of PD appear when striatal DA
is depleted 70–80% and when 50–60% of DA cell loss has
occurred in SNc [1, 2, 4, 39]. In the present work, we have
used a rat model that closely mimics the neurochemical
characteristics of early PD, producing a slow degeneration
of the dopaminergic nigrostriatal pathway over a period of
several weeks [32, 34, 40, 41]. In essence, this model of
presymptomatic PD is produced by an intrastriatal unilateral
injection of 6-OHDA, which initially induces a partial
damage(20to50%)ofDAterminalsinthestriatumfollowed
by a slow progressive degeneration of dopaminergic cells in
the ipsilateral SN [13, 32]. In these conditions, we were onlyParkinson’s Disease 9
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Figure 6: A decrease in the percentage of double labeling for TH and trkB in SNc is detected 7 days after unilateral 6-OHDA intrastriatal
injections. Photomicrographs show TH-IF cells (a), (b) and trkB-IF cells (c), (d) in rat SNc, 7 days after unilateral 6-OHDA intrastriatal
injection. (e) Merge of (a) and (c); (f) merge of (b) and (d). (a), (c), and (d) correspond to contralateral SNc while (b), (d), and (f) to
ipsilateral SNc. (a)–(f) scale bar = 50μm. SNc: substantia nigra pars compacta. (g) Quantiﬁcation of cells that coexpress TH and trkB in the
ipsilateral SNc compared to their contralateral side, 7 days after unilateral 6-OHDA or ascorbic acid (sham) intrastriatal injections to rats.
The results were expressed as the percentage of cells that coexpress TH and trkB over the number of total TH-IF cells. Number of cells with
TH-IF signals and double TH-trkB-IF signals in contralateral SNc after ascorbate injection was 365.1 ± 39.7 and 309.5 ± 39.7c e l l s / m m 2,
respectively. In the case of 6-OHDA-treated rats, number of cells with TH-IF signals and double TH-trkB-IF signals in contralateral SNc was
333.3 ± 23.8 and 277.7 ± 7.9c e l l s / m m 2,r e s p e c t i v e l y .n = 4 rats for each experimental condition. The diﬀerent experimental groups were
compared by a Kruskal-Wallis nonparametric ANOVA, followed by a U-test. ∗P<0.05 compared with sham-treated rats.10 Parkinson’s Disease
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Figure 7: Ifenprodil, an antagonist of NR2B containing NMDA receptors, prevents the decrease in trkB-IR and TH-IR cells occurring in
SNc 14 days after 6-OHDA intrastriatal injection. Positive cells for trkB and TH immunostaining in SNc were counted in coronal midbrain
slices of treated rats as described in Section 2. Four groups of rats in each case (a) and (b) were pretreated with saline solution or Ifenprodil
(5mg/kg,i.p.),1daybeforeand3,5,and7daysafterunilateral6-OHDA(blackcolumns)orascorbicacid(sham,whitecolumns)intrastriatal
administration. The IHC studies were performed 14 days after 6-OHDA or ascorbic acid injections. Results were expressed as a percentage
of trkB-IR cells (a) or TH-IR cells (b) in the ipsilateral SNc compared with the contralateral side. (a) Number of cells with trkB-IR signals
in sample areas per slice from contralateral SNc was equal to 365.1 ± 15.9, 381.0 ± 31.7, 412.7 ± 10.6, and 404.7 ± 15.9c e l l s / m m 2 in sham-
saline,6-OHDA-saline,sham-Ifenprodil,and6-OHDA-Ifenprodilrats,respectively.(b)NumberofTH-IRcellsinsampleareasperslicefrom
contralateral SNc was equal to 404.8 ± 23.8, 357.1 ± 29.8, 386.9 ± 11.9, and 369.0 ± 6.0c e l l s / m m 2 in sham-saline, 6-OHDA-saline, sham-
Ifenprodil, and 6-OHDA-Ifenprodil rats, respectively. The diﬀerent experimental groups were compared by a Kruskal-Wallis nonparametric
ANOVA, followed by a U-test. ∗P<0.05, when comparing saline-6-OHDA versus saline-sham rats. #P<0.05 when comparing saline-6-
OHDA versus Ifenprodil-6OHDA rats. n = 3 rats under each experimental condition.
able to observe a signiﬁcant reduction in the number of TH-
IR cells in SN starting fourteen days after 6-OHDA injec-
tion, in agreement with previous results from us and others
[12,13,34,40].Indeed,thisPDratmodelallowedustostudy
changes in the expression of trkB receptors in SN that might
occur prior to any reduction in the number of dopaminergic
neurons in this midbrain area.
4.2. Intrastriatal 6-OHDA Injection Induces Changes in the
Expression of TrkB in SNc. Recent studies in our laboratory
have shown an increased expression of BDNF transcripts in
SN as early as one day after 6-OHDA intrastriatal injection
[13]. However, nigral BDNF expression returned to basal
levels by 7 days after neurotoxin injection. Therefore, a
transient upregulation of BDNF expression in SN seems to
exist at early stages in this rodent model of PD. We have pro-
posed that these changes in BDNF transcripts may constitute
part of compensatory actions triggered to maintain the
survival and integrity of DA cells in SN [11, 13]. In this work
we decided to expand our knowledge on this model of pres-
ymptomatic PD by evaluating the expression of the BDNF
receptor, trkB. We detected a decrease in trkB expression in
SNc 7 days after 6-OHDA injection. This reduction in the
expression of trkB after 6-OHDA treatment does not seem to
be accounted by dopaminergic cell death as no change in the
number of TH-positive cells or in the total number of cells
was detected in SNc at this time point. Indeed, our studies
demonstrate that 83% of TH-positive cells in SNc coexpress
trkB,whichisinagreementwithpreviousresultsfromothers
[26]. No colocalization was detected in SNR, as no TH-
positive cells were observed in this SN subregion [26, 36, 37,
42]. In addition, by seven days after unilateral intrastriatal
injection with the neurotoxin it was possible to detect a
reduction in the colocalization of trkB and TH in ipsilateral
SNc compared to the control contralateral SNc. Since at this
time point we did not detect any change in the number of
TH-positive cells or in the total number of cells in this brain
region,theseresultssuggestthatthedecreaseintrkBreceptor
expressionafter6-OHDAtreatmentmightbeduetoareduc-
tion in the genic expression of this receptor in TH-posi-
tive cells in SNc.
The observation that trkB receptors begin to be down-
regulated seven days after 6-OHDA injection is intriguing
and raises the question whether this might be linked to
transient increases of BDNF expression observed in SN at
early times after neurotoxin injection [12, 13]. We have
reported a substantial increased expression of BDNF tran-
scripts in SN as early as 1–4 days after 6-OHDA intrastriatal
injection, an eﬀect that was abolished by MK-801, a nonse-
lective antagonist of NMDA receptors, but not by Ifenprodil,
selective antagonist of NR2B-containing NMDA receptors
[11–13, 43]. As judged by ISH and IHC studies, such
increases in BDNF expression appear to occur preferentiallyParkinson’s Disease 11
in SNR [12, 13]. In addition, such increases occur in parallel
with mild but signiﬁcant increases in extracellular levels
of glutamate and aspartate in SN [11, 13]. At later stages
(7 days) in this presymptomatic PD model, nigral BDNF
transcripts expression started to return to basal levels,
whereas glutamate and aspartate extracellular levels kept
increasing quite dramatically in SN [13]. This last time point
after striatal 6-OHDA injection seems to determine the initi-
ation of trkB downregulation in SN as reported in this work.
However and in contrast to BDNF upregulation, the changes
in trkB expression shown occur predominantly in SNc and
are selectively blocked by an antagonist of NR2B-containing
NMDA receptor such as Ifenprodil. Therefore, such down-
regulation of trkB in SNc after neurotoxin injection could
be triggered by an increased overﬂow of excitatory amino
acids and a parallel activation of NR2B-NMDA receptors.
Despite the previous considerations, it is not possible to
disregard that increased endogenous BDNF levels in SN may
contribute also to the neurotoxin-induced decrease of trkB
observed in this midbrain subregion. Indeed, BDNR-IR cells
in SNc and SNr remained signiﬁcantly elevated at 7 days
of this 6-OHDA presymptomatic model, although this coin-
cidedwithBDNFtranscriptsexpressionactuallyreturningto
basal levels [13]. Therefore, elevated levels of BDNF protein
in SNc might very well induce an internalization process
and a later proteolysis of the trkB receptor. Supporting this
idea, studies conducted in primary cultures of hippocampal
neurons and cerebellar granule neurons demonstrate that
exposure of these cultures to the BDNF ligand results in
a decrease both in trkB mRNA and protein and that these
changes are prevented by inhibitors of proteosomal function
[44, 45]. It remains to be established whether such BDNF-
dependent trkB internalization occurs in SNc at early times
after 6-OHDA intrastriatal injections.
It is interesting that the 6-OHDA intrastriatal adminis-
trationinducesadownregulationoftrkBreceptorspeciﬁcally
in SNc while no eﬀect is detected in SNR. According to the
data presented in this work, trkB shows a lower expression in
SNR than in SNc. As discussed before, early after neurotoxin
injectionanincreasedexpressionofBDNFtranscriptsoccurs
preferentially in SNR as compared to SNc [12, 13], while
no change is detected in trkB expression in any of the SN
subregions. Therefore, it would be possible to suggest that
early after the 6-OHDA-induced injury there is an increased
BDNF/trkB ratio in SNR compared to SNc, which might
explain the diﬀerential eﬀects induced by the toxin in each
SN subregions. Additionally, relative diﬀerences in glutamate
overﬂow and subsequent NR2B-NMDA receptors activa-
tion could also contribute to the diﬀerential trkB regulation
shown here in these SN subregions. It is interesting that
a subcellular relocation of NR2B-NMDA receptors from
synaptic to extrasynaptic sites has been reported to occur in
thestriatumofratsafteranacuteinjectionof6-OHDAinSN
[46].Itremainstobedeterminedwhethersuchphenomenon
also happens in SNc following intrastriatal 6-OHDA injec-
tion, our experimental condition. Another important con-
sideration is associated with the fact that the decrease in
trkB after 6-OHDA treatment occurs only in TH-IR cells
locatedinSNc,positioningtheDAcellsasthemaintargetsof
this downregulation. Conversely, our results show that trkB
coexists in SNR mainly with non-DAergic cells and in this
SN subregion no change is observed. Therefore, a combi-
nation of DAegic cell phenotype, BDNF/trkB ratio, local
glutamate overﬂow and relative predominance of NR2B-
NMDA receptors could contribute to the early and speciﬁc
downregulation of trkB receptors which is observed in SNc
in this experimental model of presymptomatic PD.
4.3. NR2B-Containing NMDA Receptors Mediate the Decrease
in TrkB in SNc. It has been shown that in both, the presymp-
tomatic and symptomatic phases of PD, there is an increased
glutamatergicdrive overtheSNarisingmainlyfromtheSub-
thalamic Nucleus (STN). This glutamatergic hyperactivity
seems to be a response to the misregulation of output motor
information from the basal ganglia, due to the progressive
loss of dopaminergic inputs arriving to the striatum [32,
47]. In agreement with this proposition, we have previously
shown an increase in extracellular glutamate levels in SN
in this presymptomatic model of PD [13]. We have also
provided evidence that supports the existence of a functional
coupling between increased glutamatergic drive, NMDA
receptor activation, and BDNF expression in SN in this
rodent PD model [13].
In this regard, results presented in this work indicate that
ifenprodil, a selective antagonist of NR2B-NMDA receptors,
prevents the downregulation of trkB expression in SNc after
striatal 6-OHDA injection. At the molecular level, it has been
reported that one of the promoters described for trkB is
repressedbyincreasesinintracellularcalciumlevels[48],and
therefore, it would be possible to suggest that an increased
glutamatergic drive may induce the activation of calcium
permeableNMDAreceptorsinSN,whichcouldinturnmed-
iate an increase in intracellular calcium levels ﬁnally leading
to a reduction in trkB expression in this midbrain region.
Altogether, previous and current data allow us to suggest
that glutamatergic drive and NMDA receptor activation may
exert opposing eﬀects on BDNF and trkB expression in
SN during early PD. Essentially, they could be mediating a
diﬀerential biphasic time pattern expression of the BDNF/
trkB receptor complex, which precedes DA cell death in SN
and the clinical symptoms of this neurological disease. Thus,
early after striatal 6-OHDA injections (1 to 4 days in our
rodent model of PD), increased synaptic glutamatergic
information in SN would mediate the increase in BDNF
expression, neurotrophin that may be associated with posi-
tive compensatory actions in SN. Later on (by 7 days),
overactivityofglutamatergicpathwaysinnervatingSNwould
speciﬁcallyactivateNR2B-containingNMDAreceptorscaus-
ing a downregulation of trkB receptors. This would be
consistentwiththepropositionthattheNR2B-NMDArecep-
tors are partly located extrasynaptically and that spillover
from overactive synapses might be involved in the activation
of these receptors [49–51]. Finally, a deﬁcit in BDNF-
mediated signaling may develop in SNc, which in turn might
contribute to proapoptotic actions and to nigral dopamin-
ergic neuronal death in this midbrain subregion. This is a
proposition we are currently evaluating in our lab.12 Parkinson’s Disease
4.4. Is a Coupling between NR2B-NMDA Receptors and
BDNF/TrkB Signaling Involved in the Maintenance of DA
Cell Phenotype in SNc after 6-OHDA Intrastriatal Injections?
The study we describe here raises the question whether the
NMDA receptor-mediated downregulation of trkB receptor
in SN after 6-OHDA treatment occurs as part of compen-
satory events related to the survival and functional integrity
of DA cells in SN. The changes reported here on trkB expres-
sion occurred mainly in SNc in a cellular localization coinci-
dentwiththatofTH,animportantphenotypicmarkerofDA
cells in SN. Therefore, DA cells were functionally deprived
as early as 7 days after neurotoxin injection of an important
neurotrophin receptor support via a mechanism involving
NR2B-NMDA receptor activation. At a later time point
(14 days) after 6-OHDA treatment, the number of Nissl-
stained and TH-IR cells in SNc started to decrease through
a mechanism which also involves NR2B-NMDA receptor, at
least in the case of TH-IR. As shown here, most of the TH-
IR cells coexist with trkB receptors in SNc, suggesting that an
earlier disappearance of this receptor may render these cells
more susceptible to 6-OHDA pro-oxidative eﬀects. In view
of the previous considerations, it seems no surprising that
prior treatments with an NR2B-NMDA receptor antagonist
such as Ifenprodil abolishes not only the reduction in the
expression of trkB observed in SNc after 6-OHDA treatment
but also the change in TH-IR. Both eﬀects would occur most
likely in DAergic cells located in this midbrain subregion.
It should be mentioned that the existence of a mecha-
nism which is NMDAR-dependent, but trkB-independent,
could also account in part for the reduction of TH-IR in
SNc after 6-OHDA treatment. However, by means of the
present presymptomatic PD model, it was shown that sys-
temic injection of K-252a, an inhibitor of trkB receptors,
signiﬁcantly anticipates the time point at which TH-IR
cells start to disappear in rat SNc in response to 6-OHDA
striatal injection [52]. In addition, recent observations in
experimental models of PD in adult rodents indicate that
compounds such as rasagiline and 7, 8-dihydroxyﬂavone, a
trkB agonist, may induce DAergic neuronal protection in SN
through trkB receptor activation [53, 54]. All these results
support the suggestion that trkB receptors and NR2B-
NMDA receptors may be important for the maintenance
of the DAergic phenotype during presymptomatic stages of
PD. Notwithstanding the previous considerations, further
experiments on cell viability in SNc are necessary in this PD
model with speciﬁc markers of DAergic cells other than TH
tostrengththepropositionthatNMDAreceptorsandBDNF/
trkB signaling are necessary to maintain DAergic neuronal
survival. In this regard, consistent with this idea it was
shown that old mutant mice with haploinsuﬃciency for trkB
showed a greater loss of DAergic neurons when compared to
old wild-type animals [17].
5. Conclusions
These results and those previously reported by us [13],
conducted in a rat model of PD, suggest that both BDNF
a n dt r k Be x p r e s s i o na n df u n c t i o nm a yb et i g h t l yr e g u l a t e d
in SN during the presymptomatic stages of PD. Moreover,
the results presented here give further support to the idea
that a functional coupling between NMDA receptors and
BDNF/trkB signaling may be important for the maintenance
of the dopaminergic phenotype in SNc during the presymp-
tomatic stages of this neurological disease.
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